Anti-NY-ESO-1/HLA-A02 TCR-mimic antibody therapy(Biocytogen Pharmaceuticals)

N/A

Report date: 2024/01/04 17:19:09

Base Information

Drug NameAnti-NY-ESO-1/HLA-A02 TCR-mimic antibody therapy(Biocytogen Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionAnti-HLA-A2Anti-NY-ESO-1
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha ChainCancer/testis antigen 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocytogen Pharmaceuticals (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A